New
HealthMore in Health→
Secretive Pharma Deals Could Undercut 'Most-Favored Nation' Pricing, Analysis Finds
Key Takeaways
- A new analysis reported by STAT News suggests projected savings from Trump's 'most-favored nation' drug pricing policy may be drastically reduced.
- Secretive agreements with pharmaceutical companies are cited as the reason the headline savings estimates could fall short.
- Because the deals are not public, outside analysts cannot verify the assumptions behind the savings projections.
- The analysis does not claim savings would vanish entirely, only that the projected benefits are far more uncertain than advertised.
DE
DT Editorial Team··via statnews.com